‘Phenomenal’ REDUCE-IT establishes triglyceride theory



– REDUCE-IT is a phenomenal trial and a game changer because it has shown for the first time that triglyceride reduction with an appropriate therapy – in this case icosapent ethyl – when used in appropriate doses can make a significant difference.

That’s according to Prakash C. Deedwania, MD, chief of the cardiology division at the Veterans Affairs Medical Center/University of California San Francisco Program in Fresno, who joined MDedge reporter Richard Mark Kirkner for a video interview at the American Heart Association scientific sessions.

In the large, placebo-controlled REDUCE-IT trial in patients with or at high risk for cardiovascular disease received who received 2 g of icosapent ethyl (Vascepa) twice daily or placebo saw a 25% lower risk of cardiovascular death or an ischemic event, compared with placebo.

Recommended Reading

New cholesterol guidelines expand options for primary care
MDedge Cardiology
Vitamin D, fish oil circling the drain for primary prevention
MDedge Cardiology
Revised U.S. cholesterol guidelines promote personalized risk assessment
MDedge Cardiology
Children with poor cardiorespiratory fitness have a higher risk of type 2 diabetes and cardiovascular disease
MDedge Cardiology
Empagliflozin reduces left ventricular mass
MDedge Cardiology